| Name | Title | Contact Details |
|---|
Mountain States Health Alliance (MSHA), formed in 1998, is the largest health care system in Northeast Tennessee and Southwest Virginia. Our approximately 9,000 team members, associated physicians and volunteers bring loving care to health care every day in each of our facilities.
Anatomical Chart Company is a Skokie, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Juniper Communities was founded in 1988 and operates 18 long-term care communities in NJ, FL, PA and CO. Juniper is dedicated to Nurturing the Spirit of Life in each individual served and believes the keys to healthy aging are an active body, an engaged mind, and a fulfilled spirit. The company`s mission is to serve its stakeholders, residents, families, employee associates, and investors with excellence and strong dedication to the company`s hallmarks of quality, value and innovation.
Collaborative Imaging is a radiologist owned alliance conceived by forward thinking physicians in conjunction with proven business experts to combat the growing threat of consolidation in radiology, degradation in patient care, physician burn-out, and operational inefficiencies plaguing radiologists, while providing a sustainable business model to allow its partners to realize additional revenue opportunities, all while retaining their full autonomy as an independent radiology practice.
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.